| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431806 | CELATOR PHARMS | Liposomal formulations of anthracycline agents and cytidine analogs |
Apr, 2025
(1 year, 6 months from now) | |
| US8518437 | CELATOR PHARMS | Lipid carrier compositions with enhanced blood stability |
Jun, 2026
(2 years from now) | |
| US9271931 | CELATOR PHARMS | Compositions for delivery of drug combinations |
Jan, 2027
(3 years from now) | |
| US7850990 | CELATOR PHARMS | Compositions for delivery of drug combinations |
Jan, 2027
(3 years from now) | |
| US8022279 | CELATOR PHARMS | Liposomal formulations of anthracycline agents and cytidine analogs |
Sep, 2027
(3 years from now) | |
| US8092828 | CELATOR PHARMS | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
Apr, 2029
(5 years from now) | |
| US10028912 | CELATOR PHARMS | Method of lyophilizing liposomes |
Oct, 2032
(9 years from now) | |
| US10835492 | CELATOR PHARMS | Method of lyophilizing liposomes |
Oct, 2032
(9 years from now) | |
| US10166184 | CELATOR PHARMS | Method of lyophilizing liposomes |
Oct, 2032
(9 years from now) | |
Vyxeos is owned by Celator Pharms.
Vyxeos contains Cytarabine; Daunorubicin.
Vyxeos has a total of 9 drug patents out of which 0 drug patents have expired.
Vyxeos was authorised for market use on 03 August, 2017.
Vyxeos is available in powder;intravenous dosage forms.
Vyxeos can be used as method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older, for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older, method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older, method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older.
The generics of Vyxeos are possible to be released after 15 October, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 3, 2024 |
| New Patient Population (NPP) | Mar 30, 2024 |
Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient
Market Authorisation Date: 03 August, 2017
Treatment: For the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older; Method of ad...
Dosage: POWDER;INTRAVENOUS
VYXEOS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic